Search

Search Constraints

You searched for: Author/Creator Madduri, Deepu

Search Results

2. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. Issue 5 (29th February 2020)

3. A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. Issue 9 (28th July 2020)

4. A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. (15th June 2022)

7. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Issue 10297 (24th July 2021)

8. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Issue 8 (2nd July 2020)

9. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study. Issue 12 (December 2022)

10. Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. Issue 9 (1st September 2020)